Royal Deluxe Holdings Limited 中期報告 2025 (Incorporated in the Cayman Islands with limited liability) Royal Deluxe Holdings Limited Stock code: 3789 Interim Report 2025 | 公司資料 | 2 | | --- | --- | | 摘要 | 4 | | 簡明綜合損益及其他全面收益表 | 5 | | 簡明綜合財務狀況報表 | 6 | | 簡明綜合權益變動表 | 7 | | 簡明綜合現金流量表 | 8 | | 未經審核簡明綜合中期財務報表附註 | 9 | | 管理層討論及分析 | 20 | | 其他資料 | 30 | 公司資料 董事會 執行董事 王麒銘先生 （主席） 王宇軒先生 （行政總裁， 於二零二五年十月二十三日獲委任） 周麗卿女士 審核委員會 鄺炳文先生 （主席） 黎雅明先生 蕭錦成先生 薪酬委員會 黎雅明先生 （主席） 鄺炳文先生 蕭錦成先生 王麒銘先生 提名委員會 蕭錦成先生 （主席） 黎雅明先生 鄺炳文先生 王麒銘先生 周麗卿女士 （於二零二五 ...

CHI KAN HOLDINGS LIMITED 智勤控股有限公司 (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號：9913 (於開曼群島註冊成立的有限公司) CONTENTS 目錄 Page 頁次 Corporate Information 2 公司資料 Management Discussion and Analysis 4 管理層討論及分析 Corporate Governance and Other Information 10 企業管治及其他資料 Condensed Consolidated Statement of Comprehensive Income 19 簡明合併全面收益表 Condensed Consolidated Statement of Financial Position 21 簡明合併財務狀況表 Condensed Consolidated Statement of Changes in Equity 23 簡明合併權益變動表 Condensed Consolidated S ...

Interim Report 中期報告 2025 CONTENTS 目錄 P.2 Corporate Information 公司資料 P.4 Condensed Consolidated Statement of Profit or Loss 簡明綜合損益表 P.5 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其他全面收 益表 P.6 Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 P.8 Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表 P.10 Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表 P.11 Notes to the Condensed Consolidated Interim Financial Information 簡明綜合中期財務資 ...

CHINA CHUNLAI EDUCATION GROUP CO., LTD. 中國春來教育集團有限公司 （於開曼群島註冊成立的有限公司） 股票代號 : 1969 2025 年度報告 目 錄 | | 頁次 | | --- | --- | | 公司概覽 | 2 | | 公司資料 | 3 | | 財務概要 | 5 | | 財務摘要 | 6 | | 管理層討論與分析 | 7 | | 董事及高級管理層 | 20 | | 董事會報告 | 28 | | 企業管治報告 | 53 | | 環境、社會及管治報告 | 66 | | 獨立核數師報告 | 172 | | 綜合損益及其他全面收益表 | 177 | | 綜合財務狀況表 | 178 | | 綜合權益變動表 | 180 | | 綜合現金流量表 | 181 | | 綜合財務報表附註 | 183 | | 釋義 | 233 | | 詞彙表 | 238 | 中國春來教育集團有限公司 2025年年度報告 公司概覽 本集團為中國民辦高等教育的領先提供商之一。自2004年成立起，我們已在河南省經營四所學院╱院校，在湖 北省經營兩所院校並參與江蘇省一所院校的運營。本集團院校的在校生總數從2 ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HK$1,930,578, a decrease of 6.4% compared to HK$2,062,897 in 2024[13] - EBITDA for the same period was HK$171,678, reflecting a decline of 30.7% from HK$247,906 in 2024[13] - Profit before tax dropped by 74.7% to HK$14,333 from HK$56,642 in the previous year[13] - Profit for the period decreased by 89.5% to HK$4,218 compared to HK$40,301 in 2024[13] - The loss attributable to owners of the Company was HK$10,312, a significant decline from a profit of HK$14,097 in 2024, marking a 173.1% change[13] - EBITDA margin decreased to 8.9% from 12.0% in the previous year, reflecting reduced operational efficiency[13] - Net profit margin fell to 0.2% from 2.0%, indicating a significant drop in profitability relative to revenue[13] - No dividend was declared for the period, compared to 1.0 HK cents per share in the previous year[13] Assets and Liabilities - Total assets increased to HK$5,319,342 as of September 30, 2025, up from HK$5,026,888 as of March 31, 2025[13] - Total liabilities rose to HK$3,104,274 from HK$2,821,892, indicating a growing debt level[13] Revenue Breakdown - Revenue from medical services decreased by 14.2% year-on-year to HK$1,084.2 million, attributed to softer market sentiment and the impact of previous disposals[50] - Revenue from aesthetic medical and beauty and wellness services increased by 7.3% to HK$676.5 million, accounting for 35.0% of total revenue, attributed to the acquisition of aesthetic medical business[104][108] - Revenue from veterinary and other services increased by 1.2% to HK$170.9 million, representing 8.9% of total revenue, primarily due to the expansion of veterinary services[105][109] Operational Initiatives - The Group's operational excellence initiatives included workforce restructuring and procurement governance enhancements to mitigate revenue pressure[35][36] - The Group expanded its insured service offerings through wellness, preventive health, and chronic-disease programs co-developed with insurance partners[27] - Enhanced package design and workplace health initiatives improved value propositions for employers, strengthening the Group's penetration across diversified industries[28] - Ecosystem integration strengthened cross-referral pathways among various service lines, enhancing service continuity and multi-service retention[32] Market Environment - The Group expects the operating environment in Hong Kong's private healthcare sector to remain challenging in the near term, but long-term fundamentals remain attractive due to rising healthcare expenditure and an aging population[71][74] - Cross-border healthcare integration within the Greater Bay Area is accelerating, supported by initiatives to enhance talent mobility and develop interoperable health-record frameworks[77] Share Options and Capital Management - The Company operates multiple share schemes, including the 2016 Share Option Scheme, which was terminated on May 29, 2023, with no options available for grant as of April 1, 2025, and September 30, 2025[166][169] - The Company has a total of 10,000,000 share options with various exercise periods, with the first set expiring in 2031[160] - The Group's capital management strategy includes selective divestment of non-core assets to enhance capital efficiency and improve asset quality[90] Future Outlook - The company remains confident in its long-term strategy and competitive position despite short-term market pressures, focusing on technology and operational transformation to capture long-term opportunities in the evolving healthcare landscape[101] - The Group is positioned to lead the next phase of market transformation in Hong Kong's healthcare sector, supported by ageing demographics and rising wellness awareness[98]

目 錄 | 公司資料 | 2 | | --- | --- | | 管理層討論及分析 | 3 | | 其他資料 | 8 | | 未經審核簡明綜合損益及其他全面收益表 | 13 | | 未經審核簡明綜合財務狀況表 | 14 | | 未經審核簡明綜合權益變動表 | 15 | | 未經審核簡明綜合現金流量表 | 16 | | 未經審核中期財務報告附註 | 17 | | 獨立核數師審閱報告 | 32 | 公司資料 董事 執行董事 林景生先生 （行政總裁） 譚瑞堅先生 非執行董事 鄭志明先生 （主席） 李志軒先生 呂施施女士 獨立非執行董事 周紹榮先生 黃文宗先生 陳定邦先生 董事會委員會 執行委員會 林景生先生 （主席） 譚瑞堅先生 審核委員會 黃文宗先生 （主席） 鄭志明先生 周紹榮先生 陳定邦先生 李志軒先生 薪酬委員會 陳定邦先生 （主席） 周紹榮先生 黃文宗先生 李志軒先生 提名委員會 周紹榮先生 （主席） 黃文宗先生 陳定邦先生 李志軒先生 呂施施女士 公司秘書 吳心瑜女士 授權代表 譚瑞堅先生 吳心瑜女士 核數師 國富浩華（香港）會計師事務所有限公司 根據會計及財務匯報局條例 註冊的公眾利益實體核數師 開曼 ...

Financial Performance - The company reported a revenue of approximately HKD 554.3 million for the six months ended September 30, 2025, representing a 5.1% increase from HKD 527.3 million in the same period last year[10]. - Profit attributable to equity shareholders surged to approximately HKD 1,218.1 million, a significant increase of about HKD 1,121 million compared to HKD 97.1 million in the previous year[15]. - The gross profit decreased to HKD 64.6 million, down 21.2% from HKD 82 million in the same period last year, with a gross margin decline of 3.8 percentage points to 11.7%[12]. - The net profit for the six months was HKD 1,211,274,000, significantly up from HKD 95,656,000 in 2024, reflecting a year-on-year increase of 1,166.5%[54]. - Basic earnings per share increased to 131.3 HK cents from 10.5 HK cents in the previous year, marking a substantial rise of 1,150.5%[54]. - The company recognized a share of losses from associates amounting to HKD 17,734,000, compared to a profit of HKD 40,793,000 in the previous year[53]. - The company reported a net foreign exchange loss of HKD 11,430,000 for the six months ended September 30, 2025, compared to a loss of HKD 6,683,000 in the previous year[66]. - The company's income tax expense for the six months ended September 30, 2025, was HKD 126,734,000, compared to HKD 9,874,000 for the same period in 2024, reflecting a significant increase[71]. Investments and Assets - The company achieved a notable increase in fair value gains on financial assets, rising from HKD 17.2 million to HKD 1,342.2 million, primarily due to changes in the fair value of its stake in Nantong Jianghai Capacitor Co., Ltd.[13]. - The company holds 117,442,410 shares in Nantong Jianghai, with a fair value of approximately HKD 3.9 billion as of September 30, 2025[7]. - The total assets of the group as of September 30, 2025, were approximately HKD 5,644,900,000, with liabilities of HKD 784,200,000 and total equity of HKD 4,860,700,000[21]. - The fair value of financial assets measured at fair value through profit or loss increased to HKD 4,228,020,000 as of September 30, 2025, from HKD 2,741,250,000 as of March 31, 2025[82]. - The equity investment in the listed associate in China was valued at HKD 1,283,496,000 as of September 30, 2025, an increase from HKD 1,094,244,000 as of March 31, 2025[78]. - Trade receivables as of September 30, 2025, amounted to HKD 212,855,000, with overdue receivables totaling HKD 55,722,000[88]. - Trade payables as of September 30, 2025, totaled HKD 142,735,000, with overdue payables amounting to HKD 17,306,000[89]. Capital Expenditures and Dividends - Capital expenditures for the period amounted to HKD 117.1 million, compared to HKD 106.6 million in the previous year, mainly for acquiring AI computing and related equipment[16]. - The board has decided not to recommend an interim dividend for the six months ending September 30, 2025[28]. - The company declared a final dividend of HKD 0.05 per share for the year ended March 31, 2025, totaling HKD 46,665,000, slightly down from HKD 47,141,000 in 2024[75]. - The company declared dividends amounting to HKD 45,947,000 during the period, consistent with previous distributions[57]. Strategic Initiatives - The company is strategically expanding its product portfolio to enter the automotive industry, laying the groundwork for future business growth[4]. - The group plans to enhance its market share in engineering machinery, medical equipment, and commercial appliances, while strategically entering the automotive display market[20]. - The AI computing and related business is positioned for significant growth in the rapidly expanding AI market in China, despite currently minimal revenue contribution[11]. - The group aims to reduce material procurement costs to strengthen its core cost competitiveness and maintain quality as a priority[20]. Corporate Governance and Compliance - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange listing rules[39]. - No significant non-compliance with the securities trading standard code was reported for the six months ending September 30, 2025[40]. - The audit committee consists of independent non-executive directors and has reviewed the accounting principles and practices adopted by the group[45]. - The company has adopted measures to ensure high levels of corporate governance, which are deemed crucial for its success[39]. Shareholder Information - As of September 30, 2025, the total issued shares of the company are 933,302,000[36]. - Mr. Li Guowei holds 108,504,000 shares, representing 11.63% of the company's issued share capital[30]. - Antrix Investment Limited directly holds 570,000,000 shares, accounting for 61.07% of the company's issued share capital[38]. - The company has no knowledge of any person holding 5% or more of the company's shares or related shares as of September 30, 2025[38]. Investigations and Legal Matters - The company is currently under investigation by the China Securities Regulatory Commission regarding potential false disclosures in financial reports of its associate, Suzhou Qingyue[49]. - The group has initiated a procedure to reduce its participation in Suzhou Qingyue due to an ongoing investigation related to alleged false reporting[17]. Other Financial Metrics - The company’s cash and cash equivalents decreased to HKD 286,042,000 from HKD 525,183,000, a decline of 45.4%[55]. - The company’s equity attributable to owners increased to HKD 4,778,637,000 from HKD 3,584,108,000, reflecting a growth of 33.3%[56]. - The company’s cash flow from operating activities showed a net cash outflow of HKD 5,228,000, a decrease from HKD 19,541,000 in the previous year[59]. - The company invested HKD 119,835,000 in property, plant, and equipment during the period, an increase from HKD 107,137,000 in the prior year[59].

Financial Performance - The Group reported a turnover of HK$161.00 million for the six months ended 31 October 2025, representing an increase of 4.27% compared to HK$154.41 million for the same period last year[6]. - The consolidated profit for the Period amounted to HK$77.90 million, a significant increase from HK$11.26 million for the corresponding period in 2024[6]. - Earnings per share for the Period was HK24.62 cents, compared to HK3.90 cents in 2024[6]. - Profit before tax for the period was HK$78,830,000, significantly higher than HK$11,760,000 in the previous year, representing a growth of 572.5%[86]. - Profit for the period attributable to owners of the Company was HK$77,895,000, compared to HK$11,260,000 in the prior year, marking a year-over-year increase of 691.5%[86]. - Total comprehensive income for the period attributable to owners of the Company was HK$78,549,000, compared to HK$11,580,000 in the previous year, indicating a significant increase[86]. Expenses and Costs - Staff costs increased to HK$51.63 million, representing 32.07% of the Group's turnover, down from 33.06% in 2024[8]. - Other operating expenses decreased by 8.97% to HK$37.87 million, representing 23.52% of the Group's turnover, down from 26.94% in 2024[9]. - Staff costs for the period were HK$51,632,000, slightly up from HK$51,051,000 in the previous year[86]. - Other operating expenses decreased to HK$37,871,000 from HK$41,598,000, reflecting a reduction of 8.7%[86]. Assets and Liabilities - The Group's cash and bank balances amounted to HK$70.92 million as at 31 October 2025, down from HK$78.04 million as at 30 April 2025[18]. - Total outstanding debts were HK$53.43 million as at 31 October 2025, down from HK$58.76 million as at 30 April 2025[18]. - The gearing ratio was 13.01% as at 31 October 2025, a decrease from 18.19% as at 30 April 2025[19]. - The total assets of the company as of October 31, 2025, were HK$555,674,000, an increase from HK$465,066,000 as of April 30, 2025, indicating a growth of approximately 19.4%[124]. - The net current assets rose to HK$294,577,000, up from HK$205,294,000, indicating a 43% increase[88]. - Trade receivables, net, rose to HK$73,403,000 as of 31 October 2025, compared to HK$54,575,000 as of 30 April 2025, reflecting a growth of 34.4%[148]. Investments - The net fair value gains on financial assets at fair value through profit or loss (FVTPL) were approximately HK$60.31 million, compared to HK$9.54 million in 2024[16]. - The Group's financial assets at fair value through profit or loss (FVTPL) increased significantly to HK$123,576,000 as of 31 October 2025, compared to HK$60,647,000 as of 30 April 2025[107]. - The investment in CJH, valued at approximately HK$4.38 million, generated a fair value gain of approximately HK$34.2 million during the period[37]. - The group invested HK$2.24 million in property, plant, and equipment during the period, financed mainly from internal resources[26]. Share Capital and Dividends - The company issued shares worth HK$9,010,000, increasing the share capital to HK$3,465,000 as of 31 October 2025[90]. - The Group did not recommend the payment of an interim dividend for the six months ended 31 October 2025, consistent with no dividend in 2024[144]. - As of October 31, 2025, Ms. Tung Siu Ching holds 1,800,000 ordinary shares, representing 1.00% of the issued share capital of the Company[52]. Strategic Focus and Future Plans - The Group aims to enhance operational performance by increasing production efficiency and capacity, alongside upgrading existing plant and machinery[42]. - The Group plans to strengthen its engineering and production departments to maintain competitive advantages in short lead times and high production planning flexibility[41]. - The Group will continue to explore other business opportunities to expand its principal manufacturing business and improve returns to shareholders[43]. Market and Customer Insights - The Group operates in one business segment, focusing on the manufacture and sale of integrated circuit leadframes, heatsinks, stiffeners, and related products, with customers primarily located in the USA, Hong Kong, Europe, PRC, Philippines, Malaysia, Singapore, and Thailand[110]. - Revenue from contracts with external customers under HKFRS 15 amounted to approximately HK$170,864,000, up from HK$160,646,000 in 2024, indicating a growth of about 6.8%[120]. - The PRC segment generated revenue of HK$50,790,000, a decrease from HK$54,158,000 in 2024, reflecting a decline of approximately 6.9%[115]. - Customer A in Malaysia reported revenue of HK$54,433,000 for the six months ended 31 October 2025, an increase of 13.0% from HK$47,868,000 in 2024[131]. Corporate Governance - The audit committee has reviewed the unaudited condensed consolidated financial statements for the six months ended October 31, 2025[78]. - The interests of directors and chief executives in shares and underlying shares were disclosed in accordance with the Securities and Futures Ordinance[50]. - Total remuneration for directors and key management is determined by the remuneration committee based on individual performance and market trends[175].

INTERIM REPORT 中 期 報 告 2025/26 (Incorporated in Bermuda with limited liability) Stock code 股份代號 : 858 Extrawell Pharmaceutical Holdings Limited (於百慕達註冊成立之有限公司) CONTENTS 目錄 Condensed Interim Financial Information 簡明中期財務資料 Board of Directors 董事會 Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表 2 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其他全面收益表 4 Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表 7 Condensed Consolidated Statement of ...

INTERIM REPORT 中 期 報 告 2025/2026 目錄 CONTENTS 02 公司資料 Corporate Information 04 財務摘要 Financial Highlights 05 管理層討論與分析 Management Discussion and Analysis 13 企業管治及其他資料 Corporate Governance and Other Information 27 簡明綜合財務報表審閱報告 Report on Review of Condensed Consolidated Financial Statements 29 簡明綜合損益及其他全面收益表 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 30 簡明綜合財務狀況表 Condensed Consolidated Statement of Financial Position 32 簡明綜合權益變動表 Condensed Consolidated Statement of Changes ...